Back to Dashboard

MK-1026-011/BELLWAVE-011

CLL•NCT06136559•Last updated: 2/15/2026

Recruiting

Study Design

Study Drug

Nemtabrutinib

Mechanism of Action

non-covalent BTK inhibitor

Sponsor

Merck Sharp & Dohme LLC

Design

Intervention, Phase III

Control Arm

Ibrutinib or Acalabrutinib

Criteria

Inclusion Criteria

Untreated CLL/SLL

Pending

Exclusion Criteria

Pending

Pending

Notes

Test

Enrollment

Progress6 / 7

Contact Information

Principal Investigator

陳彩雲

Study Nurse

李佳玲

Contact Tel

4620